Kinetic and structural analysis for potent antifolate inhibition of pneumocystis jirovecii, pneumocystis carinii, and human dihydrofolate reductases and their active-site variants

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 6, 2013, Pages 2669-2677

  Cody, Vivian ^a,b   Pace, Jim ^a   Queener, Sherry F ^c   Adair, Ona O ^d   Gangjee, Aleem ^d  

^a HAUPTMAN WOODWARD MEDICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c INDIANA UNIVERSITY   (United States)

^d DUQUESNE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIAMINO 6 [(2',5' DICHLORO ANILINO)METHYL]PYRIDO[2,3 D]PYRIMIDINE; DIHYDROFOLATE REDUCTASE; DIHYDROFOLATE REDUCTASE INHIBITOR; METHOTREXATE; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME KINETICS; ENZYME PURIFICATION; LIGAND BINDING; MUTATION; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS JIROVECI; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; STEADY STATE; STRUCTURE ACTIVITY RELATION;

CATALYTIC DOMAIN; CRYSTALLIZATION; FOLIC ACID ANTAGONISTS; HUMANS; KINETICS; MODELS, MOLECULAR; MUTATION; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS JIROVECII; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 84877871867     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00172-13     Document Type: Article

References (29)

1. Kovacs JA, Gill VJ, Meshnick S, Masur H. 2001. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA 286:2450-2460.
2. Hughes WT. 1991. Prevention and treatment of Pneumocystis carinii pneumonia. Annu. Rev. Med. 42:287-295.
3. Mu X-D, Wang G-F, Su L. 2011. A clinical comparative study of polymerase chain reaction assay for diagnosis of Pneumocystis pneumonia in non-AIDS patients. Chin. Med. J. 124:2683-2686.
4. Reid AB, Chen SC, Worth LJ. 2011. Pneumocystis jirovecii pneumonia in non-HIV-infected patients: New risks and diagnostic tools. Curr. Opin. Infect. Dis. 24:534-544.
5. Totet A, Duwat H, Magois E, Jounieaux V, Roux P, Raccurt C, Nevez G. 2004. Similar genotypes of Pneumocystis jirovecii in different forms of pneumocystis infection. Microbiology 150:1173-1178.
6. Benfield T, Atzori C, Miller RF, Helweg-Larsen J. 2008. Second-line salvage treatment of AIDS-associated Pneumocystis jirovecii pneumonia. J. Acquir. Immune Defic. Syndr. 48:63-67.
7. Ma L, Kovacs JA. 2000. Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase. Antimicrob. Agents Chemother. 44:3092-3096.
8. Nahimana A, Rabodonirina M, Bille J, Francioli P, Hauser PM. 2004. Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis. Antimicrob. Agents Chemother. 48:4301-4305.
9. Chan DCM, Anderson AC. 2006. Towards species-specific antifolates. Curr. Med. Chem. 13:377-398.
10. Gangjee A, Jain H, Kurup S. 2007. Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents, part I. Anticancer Agents Med. Chem. 7:523-542.
11. Gangjee A, Jain H, Kurup S. 2008. Recent advances in classical and nonclassical antifolates as antitumor and antiopportunistic infection agents, part II. Anticancer Agents Med. Chem. 8:205-231.
12. Gangjee A, Kurup S, Namjoshi O. 2007. Dihydrofolate reductase as a target for chemotherapy in parasites. Curr. Pharm. Des. 13:609-639.
13. Cody V, Pace J, Makin J, Piraino J, Queener SF, Rosowsky A. 2009. Correlations of inhibitor kinetics for Pneumocystis jirovecii and human dihydrofolate reductase with structural data for human active site mutant enzyme complexes. Biochemistry 48:1702-1711.
14. Cody V, Pace J, Chisum K, Rosowsky A. 2006. New insights into DHFR interactions: Analysis of Pneumocystis carinii and mouse DHFR complexes with NADPH and two highly potent 5-(-carboxy(alkyloxy)) trimethoprim derivatives reveals conformational correlations with activity and novel parallel ring stacking interactions. Proteins 65:959-969.
15. Gangjee A, Adair OO, Queener SF. 2003. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents. J. Med. Chem. 46:5074-5082.
16. Cody V. 2002. Structure analysis of human dihydrofolate reductase complexes with trimethoprim and epiroprim. Acta Crystallogr. A 58(Suppl): C288.
17. Cody V, Pace J, Pirano J, Queener SF. 2011. Crystallographic analysis reveals a novel second binding site for trimethoprim in active site mutants of human dihydrofolate reductase. J. Struct. Biol. 176:52-59.
18. Champness JN, Achari A, Ballantine SP, Bryant PK, Delves CJ, Stammers DK. 1994. The structure of Pneumocystis carinii dihydrofolate reductase to 1.9Å resolution. Structure 2:915-924.
19. McPhillips TM, McPhillips SE, Chiu HJ, Cohen AE, Deacon AM, Ellis PJ, Garman E, Gonzalez A, Sauter NK, Phizackerley RP, Soltis SM, Kuhn P. 2002. Blu-ice and the distributed control system: Software for data acquisition and instrument control at macromolecular crystallography beamlines. J. Synchrotron Radiat. 9:401-406.
20. Cohen AE, Ellis PJ, Miller MD, Deacon AM, Phizackerley RP. 2002. An automated system to mount cryo-cooled protein crystals on a synchrotron beamline using compact sample cassettes and a small-scale robot. J. Appl. Crystallogr. 35:720-726.
21. Gonzalez A, Moorhead P, McPhillips SE, Song J, Sharp K, Taylor JR, Adams PD, Sauter NK, Soltis SM. 2008. Web-ice: Integrated data collection and analysis for macromolecular crystallography. J. Appl. Crystallogr. 41:176-184.
22. Cody V, Luft JR, Pangborn W. 2005. Understanding the role of leu22 variants in methotrexate resistance: Comparison of wild-type and leu22arg variant mouse and human dihydrofolate reductase ternary crystal complexes with methotrexate and NADPH. Acta Crystallogr. D 61:147-155.
23. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AG, McCoy A, McNicholas SJ, Murshudov GN, Pannu NS, Potterton EA, Powell HR, Read RJ, Vagin A, Wilson KS. 2011. Overview of the CCP4 suite and current developments. Acta Crystallogr. D 67:234-242.
24. Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010. Features and development of COOT. Acta Crystallogr. D 66:486-501.
25. Schuettelkopf AW, van Aalten DMF. 2004. PRODRG: A model tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D 60:1355-1363.
26. Lovell SC, Davis IW, Arendall WB, III, de Bakker PI, Word JM, Prisant MG, Richardson JS, Richardson DC. 2003. Structure validation by C? geometry: Phi, psi and C deviation. Proteins 50:437-450.
27. Cody V, Schwalbe CH. 2006. Structural characteristics of antifolate dihydrofolate reductase enzyme interactions. Crystallogr. Rev. 12:301-333.
28. Cody V, Galitsky N, Rak D, Luft JR, Pangborn W, Queener SF. 1999. Ligand induced conformational changes in the crystal structures of Pneumocystis carinii dihydrofolate reductase complexes with folate and NADP?. Biochemistry 38:4303-4312.
29. Mharakurwa S, Kumwenda T, Mkulama MAP, Musapa M, Chishimba S, Shiff CJ, Sullivan DJ, Thuma PE, Liu K, Agre P. 2011. Malaria antifolate resistance with contrasting Plasmodium falciparum dihydrofolate reductase (DHFR) polymorphisms in humans and Anopheles mosquitoes. Proc. Natl. Acad. Sci. U. S. A. 108:18796-18801.